DE60213402D1 - Neue polynukleotide und polypeptide des ifn alpha-17-gens - Google Patents
Neue polynukleotide und polypeptide des ifn alpha-17-gensInfo
- Publication number
- DE60213402D1 DE60213402D1 DE60213402T DE60213402T DE60213402D1 DE 60213402 D1 DE60213402 D1 DE 60213402D1 DE 60213402 T DE60213402 T DE 60213402T DE 60213402 T DE60213402 T DE 60213402T DE 60213402 D1 DE60213402 D1 DE 60213402D1
- Authority
- DE
- Germany
- Prior art keywords
- gene
- polypeptides
- new
- ifn alpha
- new polynucleotides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Physics & Mathematics (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0105516A FR2823764B1 (fr) | 2001-04-24 | 2001-04-24 | Nouveaux polynucleotides et polypeptides du gene ifn alpha-17 |
FR0105516 | 2001-04-24 | ||
PCT/EP2002/005229 WO2002086156A2 (en) | 2001-04-24 | 2002-04-23 | New polynucleotides and polypeptides of the ifn$g(a)-17 gene |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60213402D1 true DE60213402D1 (de) | 2006-09-07 |
DE60213402T2 DE60213402T2 (de) | 2007-08-23 |
Family
ID=8862643
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60213402T Expired - Fee Related DE60213402T2 (de) | 2001-04-24 | 2002-04-23 | Neue polynukleotide und polypeptide des ifn alpha-17-gens |
Country Status (22)
Country | Link |
---|---|
US (2) | US7371819B2 (de) |
EP (1) | EP1390543B1 (de) |
JP (1) | JP2004533240A (de) |
KR (1) | KR20030093328A (de) |
CN (1) | CN1509337A (de) |
AT (1) | ATE334231T1 (de) |
AU (1) | AU2002338442B2 (de) |
BR (1) | BR0209097A (de) |
CA (1) | CA2444235A1 (de) |
CY (1) | CY1107335T1 (de) |
DE (1) | DE60213402T2 (de) |
DK (1) | DK1390543T3 (de) |
ES (1) | ES2268054T3 (de) |
FR (1) | FR2823764B1 (de) |
IL (2) | IL158415A0 (de) |
MX (1) | MXPA03009731A (de) |
NO (1) | NO20034692L (de) |
NZ (1) | NZ529051A (de) |
PT (1) | PT1390543E (de) |
RU (1) | RU2328528C2 (de) |
WO (1) | WO2002086156A2 (de) |
ZA (1) | ZA200308114B (de) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7087726B2 (en) | 2001-02-22 | 2006-08-08 | Genentech, Inc. | Anti-interferon-α antibodies |
US8551469B2 (en) | 2001-02-28 | 2013-10-08 | Superlab Far East Limited | Treatment of tumors and viral diseases with recombinant interferon alpha |
FR2822845B1 (fr) * | 2001-03-30 | 2003-12-12 | Genodyssee | Nouveaux polynucleotides comportant des polymorphismes de type snp fonctionnels dans la sequence nucleotidique du gene ifn-alpha-21 ainsi que de nouveaux polypeptides codes par ces polynucleotides et leurs utilisations therapeutiques |
EP1418428A1 (de) * | 2002-11-07 | 2004-05-12 | GenOdyssee | Verfahren zur Bereitstellung von natürlichen therapeutischen Agenzien mit hohem therapeutischen Index |
CN102101886A (zh) * | 2009-12-18 | 2011-06-22 | 四川辉阳生命工程股份有限公司 | 构象改变的重组干扰素晶体、其三维结构及应用 |
EP3559049A4 (de) | 2011-10-28 | 2019-12-04 | Teva Pharmaceuticals Australia Pty Ltd | Polypeptidkonstrukte und anwendungen davon |
TW201427681A (zh) | 2013-01-07 | 2014-07-16 | Superlab Far East Ltd | 用空間構象改變的重組干擾素治療腫瘤的方法 |
AU2013388126B2 (en) | 2013-04-29 | 2019-03-07 | Teva Pharmaceuticals Australia Pty Ltd. | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2b |
US11117975B2 (en) | 2013-04-29 | 2021-09-14 | Teva Pharmaceuticals Australia Pty Ltd | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B |
UA119352C2 (uk) | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину |
KR102639037B1 (ko) | 2014-10-29 | 2024-02-20 | 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 | 인터페론 α2b 변이체 |
RU2620073C2 (ru) * | 2015-06-02 | 2017-05-22 | Федеральное государственное бюджетное учреждение "Государственный научный центр Институт иммунологии" Федерального медико-биологического агентства России | Оптимизированный ген, кодирующий рекомбинантный белок - аналог интерферона альфа-17 человека |
CN107653323B (zh) * | 2016-07-23 | 2021-05-04 | 华中农业大学 | 团头鲂转铁蛋白基因snp分子标记及其应用 |
CA3115089A1 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | Dll3 single domain antibodies and therapeutic compositions thereof |
AU2019356573A1 (en) | 2018-10-11 | 2021-05-27 | Inhibrx, Inc. | PD-1 single domain antibodies and therapeutic compositions thereof |
TW202028246A (zh) | 2018-10-11 | 2020-08-01 | 美商英伊布里克斯公司 | B7h3單域抗體及其治療性組合物 |
CN113518647A (zh) | 2018-10-11 | 2021-10-19 | 印希比股份有限公司 | 5t4单域抗体及其治疗性组合物 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4801685A (en) * | 1981-08-14 | 1989-01-31 | Hoffmann-La Roche Inc. | Microbial production of mature human leukocyte interferon K and L |
JPS6156199A (ja) * | 1984-08-27 | 1986-03-20 | Shionogi & Co Ltd | 新規ヒトインタ−フエロンα類 |
DE69616276T2 (de) * | 1995-02-09 | 2002-12-12 | Novartis Ag | Verfahren zur produktion von proteinen |
US6299869B1 (en) * | 1997-12-08 | 2001-10-09 | Genentech, Inc. | Human interferon-epsilon: a type I interferon |
WO2000039280A2 (en) * | 1998-12-31 | 2000-07-06 | Viragen, Inc. | Leukocyte-derived interferon preparations |
MXPA02003492A (es) * | 1999-10-07 | 2002-08-20 | Maxygen Inc | Homologos de interferon-alfa. |
-
2001
- 2001-04-24 FR FR0105516A patent/FR2823764B1/fr not_active Expired - Fee Related
-
2002
- 2002-04-23 EP EP02742996A patent/EP1390543B1/de not_active Expired - Lifetime
- 2002-04-23 MX MXPA03009731A patent/MXPA03009731A/es unknown
- 2002-04-23 CA CA002444235A patent/CA2444235A1/en not_active Abandoned
- 2002-04-23 CN CNA028102193A patent/CN1509337A/zh active Pending
- 2002-04-23 KR KR10-2003-7013862A patent/KR20030093328A/ko active IP Right Grant
- 2002-04-23 AU AU2002338442A patent/AU2002338442B2/en not_active Ceased
- 2002-04-23 WO PCT/EP2002/005229 patent/WO2002086156A2/en active IP Right Grant
- 2002-04-23 NZ NZ529051A patent/NZ529051A/en unknown
- 2002-04-23 DE DE60213402T patent/DE60213402T2/de not_active Expired - Fee Related
- 2002-04-23 DK DK02742996T patent/DK1390543T3/da active
- 2002-04-23 AT AT02742996T patent/ATE334231T1/de not_active IP Right Cessation
- 2002-04-23 IL IL15841502A patent/IL158415A0/xx unknown
- 2002-04-23 ES ES02742996T patent/ES2268054T3/es not_active Expired - Lifetime
- 2002-04-23 RU RU2003133982/13A patent/RU2328528C2/ru active
- 2002-04-23 PT PT02742996T patent/PT1390543E/pt unknown
- 2002-04-23 BR BR0209097-0A patent/BR0209097A/pt not_active IP Right Cessation
- 2002-04-23 JP JP2002583669A patent/JP2004533240A/ja active Pending
-
2003
- 2003-10-14 IL IL158415A patent/IL158415A/en not_active IP Right Cessation
- 2003-10-17 ZA ZA200308114A patent/ZA200308114B/en unknown
- 2003-10-20 NO NO20034692A patent/NO20034692L/no not_active Application Discontinuation
- 2003-10-24 US US10/691,653 patent/US7371819B2/en not_active Expired - Fee Related
-
2006
- 2006-10-12 CY CY20061101453T patent/CY1107335T1/el unknown
-
2008
- 2008-04-07 US US12/098,557 patent/US20090004156A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN1509337A (zh) | 2004-06-30 |
FR2823764A1 (fr) | 2002-10-25 |
WO2002086156A3 (en) | 2003-11-27 |
IL158415A0 (en) | 2004-05-12 |
FR2823764B1 (fr) | 2003-12-12 |
AU2002338442B8 (en) | 2002-11-05 |
NO20034692D0 (no) | 2003-10-20 |
NO20034692L (no) | 2003-12-19 |
CY1107335T1 (el) | 2012-12-19 |
NZ529051A (en) | 2005-09-30 |
US20040110715A1 (en) | 2004-06-10 |
EP1390543A2 (de) | 2004-02-25 |
RU2003133982A (ru) | 2005-01-20 |
US20090004156A1 (en) | 2009-01-01 |
ES2268054T3 (es) | 2007-03-16 |
WO2002086156A2 (en) | 2002-10-31 |
US7371819B2 (en) | 2008-05-13 |
IL158415A (en) | 2009-06-15 |
EP1390543B1 (de) | 2006-07-26 |
DK1390543T3 (da) | 2006-11-27 |
BR0209097A (pt) | 2005-04-19 |
CA2444235A1 (en) | 2002-10-31 |
ZA200308114B (en) | 2005-01-17 |
RU2328528C2 (ru) | 2008-07-10 |
KR20030093328A (ko) | 2003-12-06 |
PT1390543E (pt) | 2006-12-29 |
DE60213402T2 (de) | 2007-08-23 |
ATE334231T1 (de) | 2006-08-15 |
JP2004533240A (ja) | 2004-11-04 |
AU2002338442B2 (en) | 2007-06-28 |
MXPA03009731A (es) | 2005-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE435923T1 (de) | Neue polynukleotide und polypeptide des erythropoietingens | |
CY1107335T1 (el) | ΝΕΑ ΠΟΛΥΝΟΥΚΛΕΟΤΙΔΙΑ ΚΑΙ ΠΟΛΥΠΕΠΤΙΔΙΑ ΤΟΥ ΓΟΝΙΔΙΟΥ IFNα-17 | |
CY1105650T1 (el) | ΝΕΑ ΠΟΛΥΝΟΥΚΛΕΟΤΙΔΙΑ ΚΑΙ ΠΟΛΥΠΕΠΤΙΔΙΑ ΤΟΥ ΓΟΝΙΔΙΟΥ IFNα-21 | |
DK1129190T3 (da) | Human TSLP DNA og polypeptider | |
DK1005540T3 (da) | IKK-beta-proteiner, nukleinsyrer og fremgangsmåder | |
BRPI0412401A (pt) | polipeptìdeos da amilase exoespecìficos, ácidos nucléicos que codificam tais polipeptìdeos e usos dos mesmos | |
DE69926480D1 (de) | Acpl dna und polypeptide | |
NO20073808L (no) | BCMA polypeptider og anvendelser derav | |
DE60235297D1 (de) | Auf lps-reagierendes chs1/beige-ähnliches anker-gen und therapeutische anwendungen davon | |
ATE417618T1 (de) | Faktor-viii-polypeptide auf hohem expressionsniveau codierende nukleinsäure- und aminosäuresequenzen und verwendungsverfahren | |
WO2002095067A3 (en) | INTERFERON α-14 POLYMORPHISM | |
CY1107594T1 (el) | DNA ΚΑΙ ΠΟΛΥΠΕΠΤΙΔΙΑ IL-1η | |
WO2003000896A3 (en) | POLYNUCLEOTIDES AND POLYPEPTIDES OF THE IFNα-5 GENE | |
WO2002101048A3 (en) | NEW POLYNUCLEOTIDES AND POLYPEPTIDES OF THE IFNα-7 GENE | |
WO2002083733A3 (en) | Polynucleotides and polypeptides of the ifnalpha-6 gene | |
EP1236800A3 (de) | Für Interferon alfa 2 codierende Nukleinsäuren die Einzelnukleotidpolymorphismen enthalten und Methoden zu deren Verwendung | |
DE69935213D1 (de) | Basb019 proteine und gene aus moraxella catarrhalis, antigene, antikörper, und verwendungen | |
WO2002101002A3 (en) | Identification of snps the hgv-v gene | |
DE60222669D1 (de) | Asthma-assoziiertes gen | |
DK2186898T3 (da) | Blomstrings-induktion | |
GB2441941A (en) | An isolated recombinant vaccinia virus complement control protein (HRVCP) polypeptide | |
WO2002085943A3 (en) | Nucleic acids of the human abcc12 gene, vectors containing such nucleic acids and uses thereof | |
WO2003091393A3 (en) | Nucleic “acid molecules encoding human proteins, and uses thereof” | |
SG144715A1 (en) | Recombinant nucleocapsid protein and g glycoprotein of nipah virus | |
WO2002077193A8 (en) | Isolated human ras-like proteins, nucleic acid molecules encoding these human ras-like proteins, and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8328 | Change in the person/name/address of the agent |
Representative=s name: MEISSNER, BOLTE & PARTNER GBR, 80538 MUENCHEN |
|
8339 | Ceased/non-payment of the annual fee |